Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has granted inducement awards to seven new employees under its 2023 Inducement Plan. The awards consist of stock options to purchase up to 48,600 shares of common stock.
The stock options feature a four-year vesting schedule, with 25% of shares vesting after one year and the remaining 1/48th vesting monthly over the subsequent 36 months, contingent on continued employment with Syndax.
Syndax Pharmaceuticals (NASDAQ: SNDX), un'azienda biofarmaceutica in fase commerciale specializzata in terapie oncologiche, ha assegnato premi di incentivo a sette nuovi dipendenti nell'ambito del suo Piano di Incentivo 2023. I premi consistono in opzioni su azioni per l'acquisto di fino a 48.600 azioni ordinarie.
Le opzioni azionarie prevedono un piano di maturazione quadriennale, con il 25% delle azioni che maturano dopo un anno e il restante 1/48 che matura mensilmente nei successivi 36 mesi, a condizione che il dipendente rimanga impiegato presso Syndax.
Syndax Pharmaceuticals (NASDAQ: SNDX), una compañía biofarmacéutica en etapa comercial enfocada en terapias contra el cáncer, ha otorgado premios de incentivo a siete nuevos empleados bajo su Plan de Incentivos 2023. Los premios consisten en opciones sobre acciones para comprar hasta 48,600 acciones ordinarias.
Las opciones sobre acciones cuentan con un calendario de adquisición de derechos de cuatro años, con el 25% de las acciones que se adquieren después de un año y el restante 1/48 que se adquiere mensualmente durante los siguientes 36 meses, condicionado a la continuidad laboral con Syndax.
Syndax Pharmaceuticals (NASDAQ: SNDX)는 암 치료에 중점을 둔 상업 단계의 바이오제약 회사로, 2023년 유인 계획에 따라 7명의 신입 직원에게 유인 보상을 부여했습니다. 이 보상은 최대 48,600주의 보통주를 매수할 수 있는 주식 매수 선택권으로 구성되어 있습니다.
주식 매수 선택권은 4년간의 권리 취득 일정이 적용되며, 25%는 1년 후에 취득되고, 나머지 1/48은 이후 36개월 동안 매월 취득되며, Syndax에서 계속 근무하는 조건입니다.
Syndax Pharmaceuticals (NASDAQ: SNDX), une société biopharmaceutique en phase commerciale spécialisée dans les thérapies contre le cancer, a accordé des récompenses d'incitation à sept nouveaux employés dans le cadre de son Plan d'Incitation 2023. Ces récompenses consistent en des options d'achat d'actions permettant d'acquérir jusqu'à 48 600 actions ordinaires.
Les options d'achat d'actions suivent un calendrier d'acquisition sur quatre ans, avec 25% des actions acquises après un an et le reste, soit 1/48, acquis mensuellement sur les 36 mois suivants, sous réserve de la poursuite de l'emploi chez Syndax.
Syndax Pharmaceuticals (NASDAQ: SNDX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase mit Schwerpunkt auf Krebstherapien, hat im Rahmen seines Inducement-Plans 2023 Anreizprämien an sieben neue Mitarbeiter vergeben. Die Prämien bestehen aus Aktienoptionen zum Kauf von bis zu 48.600 Stammaktien.
Die Aktienoptionen haben einen vierjährigen Vesting-Zeitplan, wobei 25% der Aktien nach einem Jahr vesten und die restlichen 1/48 monatlich über die folgenden 36 Monate vesten, vorausgesetzt, die Beschäftigung bei Syndax wird fortgesetzt.
- None.
- None.
NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2025 the Company granted inducement awards to purchase up to 48,600 shares of common stock to seven new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
FAQ
What type of inducement awards did Syndax Pharmaceuticals (SNDX) grant in August 2025?
How many employees received Syndax (SNDX) inducement awards in August 2025?
What is the vesting schedule for Syndax's (SNDX) August 2025 inducement awards?
When did Syndax Pharmaceuticals (SNDX) grant these inducement awards?
